Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
China Resources Pharmaceutical Group Ltd. reported its unaudited interim results for the first half of 2025, showing a slight increase in revenue to RMB 131.87 billion compared to the previous year. Despite the revenue growth, the company’s net profit decreased to RMB 5.05 billion, attributed to higher selling and distribution expenses, and other losses. The results highlight challenges in maintaining profitability amidst rising operational costs, which could impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is known for its comprehensive range of healthcare solutions, catering to both domestic and international markets.
Average Trading Volume: 12,295,656
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.23B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.